 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || Zioptan (tafluprost) / Santen, Merck (MSD)
Clinical, Journal, Patient reported outcomes: Efficacy, Safety and Patient-Reported Outcomes with Preservative-Free (PF) Tafluprost or PF-Dorzolamide/Timolol Compared with Preserved Latanoprost: A Prospective Multicenter Study in Korean Glaucoma Patients with Ocular Surface Disease. (Pubmed Central) - Feb 27, 2022
No new safety concerns were observed. PF-tafluprost and PF-dorzolamide/timolol showed statistically and clinically significant reductions in OSDI compared with P-latanoprost in Korean glaucoma patients with OSD.
- |||| latanoprost/dorzolamide (CKD-351) / Chong Kun Dang
New P2 trial: A Clinical Study to Evaluate the Efficacy and Safety of CKD-351 (clinicaltrials.gov) - Jun 24, 2020
P2, N=100, Recruiting, Sponsor: Chong Kun Dang Pharmaceutical
- |||||||||| latanoprost/dorzolamide (CKD-351) / Chong Kun Dang
New P3 trial: A Clinical Study to Evaluate the Efficacy and Safety of CKD-351 (clinicaltrials.gov) - Dec 3, 2018
P3, N=384, Not yet recruiting, Sponsor: Chong Kun Dang Pharmaceutical